<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04559126</url>
  </required_header>
  <id_info>
    <org_study_id>EDP 297-001</org_study_id>
    <nct_id>NCT04559126</nct_id>
  </id_info>
  <brief_title>A Study of EDP-297 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study of Orally Administered EDP-297 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (SAD), Multiple Ascending Doses (MAD), and the Effect of Food on EDP-297 Pharmacokinetics in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enanta Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PRA Health Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Enanta Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blind, placebo-controlled study. It will assess the&#xD;
      safety, tolerability, and pharmacokinetics of orally administered single and multiple doses&#xD;
      of EDP-297 in healthy adult subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first phase assesses single ascending doses of EDP-297 or placebo in healthy subjects. A&#xD;
      &quot;fasted&quot; and &quot;fed&quot; two-part cohort will also assess food effect.&#xD;
&#xD;
      The second phase assesses multiple ascending doses of EDP-297 or placebo for 14-days in&#xD;
      healthy subjects.&#xD;
&#xD;
      Each cohort within each phase will enroll a total of 8 subjects who will be randomized to&#xD;
      receive EDP-297 or placebo. The cohort assessing food effect will enroll 10 subjects&#xD;
      randomized to receive EDP-297 or placebo&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 8, 2020</start_date>
  <completion_date type="Actual">June 21, 2021</completion_date>
  <primary_completion_date type="Actual">June 21, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measured by adverse events</measure>
    <time_frame>Up to 8 Days in SAD Cohorts</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety measured by adverse events</measure>
    <time_frame>Up to 21 Days in MAD Cohorts</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of EDP-297</measure>
    <time_frame>Up to 6 Days in SAD Cohorts</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of EDP-297</measure>
    <time_frame>Up to 18 Days in MAD Cohorts</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of EDP-297</measure>
    <time_frame>Up to 6 Days in SAD Cohorts</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of EDP-297</measure>
    <time_frame>Up to 18 Days in MAD Cohorts</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>NASH - Nonalcoholic Steatohepatitis With Liver Fibrosis</condition>
  <arm_group>
    <arm_group_label>EDP-297 SAD Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EDP-297 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5 and Dose 6 oral solution, once daily in one single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP-297 MAD Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EDP-297 Dose 1, Dose 2 and Dose 3 oral solution, once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP-297 SAD Placebo Cohort</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo, oral solution, once daily in one single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP-297 MAD Placebo Cohort</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo, oral solution, once daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP-297</intervention_name>
    <description>EDP-297 Oral solution</description>
    <arm_group_label>EDP-297 MAD Cohorts</arm_group_label>
    <arm_group_label>EDP-297 SAD Cohorts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo to match EDP-297</description>
    <arm_group_label>EDP-297 MAD Placebo Cohort</arm_group_label>
    <arm_group_label>EDP-297 SAD Placebo Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  An informed consent document signed and dated by the subject.&#xD;
&#xD;
          -  Healthy male and female subjects of any ethnic origin between the ages of 18 and 65&#xD;
             years, inclusive.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically relevant evidence or history of illness or disease.&#xD;
&#xD;
          -  Pregnant or nursing females.&#xD;
&#xD;
          -  History of febrile illness within 7 days prior to the first dose of study drug or&#xD;
             subjects with evidence of active infection.&#xD;
&#xD;
          -  A positive urine drug screen at screening or Day -2.&#xD;
&#xD;
          -  Current tobacco smokers or use of tobacco within 1 months prior to screening.&#xD;
&#xD;
          -  Any condition possibly affecting drug absorption (e.g., gastrectomy, cholecystectomy).&#xD;
&#xD;
          -  History of regular alcohol consumption exceeding 14 drinks/week for females and 21&#xD;
             drinks/week for males within 6 months of Screening.&#xD;
&#xD;
          -  Participation in a clinical trial within 30 days prior to the first dose of study&#xD;
             drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enanta Pharmaceuticals, Inc</last_name>
    <role>Study Director</role>
    <affiliation>Enanta Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2020</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>&quot;First-in-Human&quot;</keyword>
  <keyword>Single Ascending Dose</keyword>
  <keyword>Multiple Ascending Dose</keyword>
  <keyword>Healthy Volunteer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

